CAR T-cell therapy to prevent relapse in high-risk B-cell ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have B-cell acute lymphoblastic leukemia (ALL) that is high-risk and newly diagnosed, and you should be in your first remission with very few leukemia cells left in your bone marrow (less than 5% blasts).
- Your leukemia must have at least one high-risk feature, like certain chromosome changes (e.g., KMT2A rearrangement, complex changes, or Philadelphia-like ALL), a TP53 mutation, or persistent signs of leukemia after initial treatment (measurable residual disease or MRD).
- You need to be in fairly good health – able to be up and about at least half the day (performance status 0, 1, or 2).
- Your liver and kidneys must be working well enough, and your leukemia cells must have the CD19 protein on their surface.
- You cannot be pregnant or breastfeeding, and you must not have active hepatitis B, C, or HIV infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
This trial tests a new CAR T-cell therapy (KITE-753) for adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or not responded to previous treatments. The therapy uses your own immune cells, modified to find and attack leukemia cells, and may offer a new option when standard treatments have stopped working.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This trial tests a new CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell acute lymphoblastic leukemia who have achieved their first complete remission after standard chemotherapy. The goal is to see if this therapy can keep the leukemia from coming back.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
Hear when a new Acute Lymphocytic Leukemia (ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.